http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108853510-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2018-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108853510-B |
| titleOfInvention | Combination of NMDAR inhibitors and T-type calcium channel inhibitors for depression treatment and drugs |
| abstract | The present invention provides a pharmaceutical composition for treating depression, comprising: component (a) N-methyl-D-aspartate receptor inhibitor; and component (b) T-type calcium channel inhibitor An agent wherein the therapeutically effective amount of at least one of the components (a) and (b) administered to the subject is lower than the therapeutically effective amount of the component administered in the absence of the other component. The present invention also provides the use of component (a) N-methyl-D-aspartate receptor inhibitor; and component (b) T-type calcium ion channel inhibitor in combination for preparing a medicine for treating depression . The present invention also provides a method of treating depression with the medicament or pharmaceutical composition. |
| priorityDate | 2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.